Form **8937**
(December 2017)
Department of the Treasury
Internal Revenue Service

Report of Organizational Actions Affecting Basis of Securities

▶ See separate instructions.

OMB No. 1545-0123

Part I Reporting Issuer

1 Issuer's name VYNE THERAPEUTICS INC. (NOW YARROW BIOSCIENCE, INC .)	**2** Issuer's employer identification number (EIN) 45-3757789

3 Name of contact for additional information TYLER ZERONDA	**4** Telephone No. of contact (203) 433-7577	**5** Email address of contact INFO@YARROWBIOSCIENCE.COM

6 Number and street (or P.O. box if mail is not delivered to street address) of contact 470 JAMES STREET, SUITE 007	**7** City, town, or post office, state, and ZIP code of contact NEW HAVEN, CT 06513

8 Date of action JULY 24, 2026	**9** Classification and description 1-FOR-50 REVERSE STOCK SPLIT (COMMON STOCK)

10 CUSIP number SEE LINE 19 BELOW	**11** Serial number(s)	**12** Ticker symbol SEE ATTACHMENT	**13** Account number(s)

Part II Organizational Action Attach additional statements if needed. See back of form for additional questions.

14 Describe the organizational action and, if applicable, the date of the action or the date against which shareholders' ownership is measured for the action ▶ SEE ATTACHMENT

15 Describe the quantitative effect of the organizational action on the basis of the security in the hands of a U.S. taxpayer as an adjustment per share or as a percentage of old basis ▶ SEE ATTACHMENT

16 Describe the calculation of the change in basis and the data that supports the calculation, such as the market values of securities and the valuation dates ▶ SEE ATTACHMENT

Part II **Organizational Action** *(continued)*

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶ SEE ATTACHMENT

18 Can any resulting loss be recognized? ▶ SEE ATTACHMENT

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶ SEE ATTACHMENT

Sign Here

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Signature ▶ Date ▶ 09/03/26

Print your name ▶ TYLER ZERONDA Title ▶ CFO

Paid Preparer Use Only

Print/Type preparer's name	Preparer's signature	Date	Check ☐ if self-employed	PTIN
MATTHEW SCALITI		09/03/26		P00960286
Firm's name ▶ RSM US LLP			Firm's EIN ▶	42-0714325
Firm's address ▶ 333 THORNALL ST., 6TH FLOOR EDISON, NJ 08837			Phone no.	732-515-7300

Send Form 8937 (including accompanying statements) to: Department of the Treasury, Internal Revenue Service, Ogden, UT 84201-0054

VYNE THERAPEUTICS INC. (NOW YARROW BIOSCIENCE, INC.)
EIN: 45-3757789
Attachment to Form 8937

The information contained herein is provided pursuant to the requirements of Section 6045B of the Internal Revenue Code of 1986, as amended (the “Code”). This attachment includes a general summary of certain U.S. federal income tax laws and regulations relevant to the Reverse Stock Split (as defined below) and the tax basis of Vyne Therapeutics, Inc. (the “Company”) common stock, for a beneficial owner of Company common stock (each a “Stockholder”). This attachment does not constitute tax advice and does not purport to be complete or to describe the consequences that may apply to particular categories of Stockholders. The Issuer does not provide tax advice to its Stockholders, and any example provided below is merely illustrative. Stockholders are urged to consult their own tax advisors regarding the particular consequences to them of the Reverse Stock Split, including the applicability and the effect of all U.S. federal, state, local, and foreign tax laws.

LINE 12 – VYNE prior to the merger; YARW following the merger/name change

LINE 14

PLEASE NOTE THIS FORM RELATES SOLEY TO THE 1-50 REVERSE STOCK SPLIT FOR FORMER VYNE THERAPEUTICS, INC. SHAREHOLDERS. PLEASE REFER TO THE OTHER FILINGS ON THIS SITE TO DETERMINE THE EFFECT OF (1) THE CASH DISTRIBUTIONS TO PRIOR VYNE THERAPEUTICS, INC. SHAREHOLDERS AND (2) THE CONVERSIONS OF VYNE THERAPEUTICS SHARES INTO YARROW BIOSCIENCE, INC. SHARES;.

a. On July 24, 2026, Vyne Therapeutics, Inc. (now Yarrow Bioscience, Inc.) (the "Company" or "VYNE") effected a 1-for-50 reverse stock split for its common stock. No fractional shares were issued in the reverse stock split. Stockholders who would otherwise be entitled to a fractional share as a result of the reverse stock split received cash in lieu thereof. In addition, effective as of the reverse stock split, proportionate adjustments were made to the exercise prices and number of shares of the Company's common stock underlying the Company's outstanding equity and warrant awards for common stock, as well as the number of common stock issuable under the Company's stock incentive plan and employee stock purchase plan.
b. The Reverse Stock Split occurred on July 24, 2026, and the Company’s common stock began trading on a split-adjusted basis when the NASDAQ Global Select Market opened on July 27, 2026.
c. The CUSIP number for the Company's common stock changed from 92941V308 to 92941V407.
d. Following the Reverse Stock Split and the closing of the merger with Yarrow Bioscience, Inc., VYNE changed its name to Yarrow Bioscience, Inc., and the Company common stock commenced trading on a post-merger basis under the ticker symbol YARW on July 28, 2026.

LINE 15

Upon the effective time of the reverse stock split, every fifty (50) shares of common stock of the Company automatically converted to one (1) share of common stock. Assuming the reverse stock split qualifies as a reorganization within the meaning of Section 368(a) of the Internal Revenue

Code of 1986, as amended (the “Code”), each Company's stockholder whose common stock was converted in the reverse stock split must allocate the aggregate tax basis in its common stock held immediately before the reverse stock split among the shares of common stock immediately held after the reverse stock split (including any fractional share interest for which cash in lieu was deemed to be received for federal income tax purposes).

LINE 16

Assuming the reverse stock split qualifies as a reorganization with the meaning of Section 368 of the Code, the Company’s stockholders with blocks of pre-split common stock not divisible by fifty (50) which reflect pre-split common stock acquired at different times or different prices must replicate such blocks of pre-split common stock in the post-split common stock received in a manner that preserves, to the greatest extent possible, the basis of a particular block of pre-split common stock in one or more post-split common stock shares received in exchange therefor. This may require the aggregate basis in one block of pre-split common stock to be allocated to post-split common stock in a manner where some post-split blocks of common stock have split basis and holding period segments.

LINE 17

Sections 358, 368(a), 354 and 1001.

LINE 18

Assuming the reverse stock split qualifies as a reorganization within the meaning of Section 368(a) of the Code, no loss may be recognized except to the extent of any cash received in lieu of fractional shares.

LINE 19

a. The Reverse Stock Split is reportable for a Stockholder’s taxable year that includes the July 24, 2026 Reverse Stock Split date.

b. Part I, Box 10 – The CUSIP number for the Company common stock prior to the Reverse Stock Split was 92941V308; the CUSIP number for the Company common stock after the Reverse Stock Split is 92941V407.

c. Information contained within this Form 8937 should not be interpreted as tax advice. Stockholders are encouraged to consult with their own tax advisors regarding specific tax consequences of the Reverse Stock Split, based on their specific facts and circumstances.

d. As an example – assume a shareholder held 200 shares of Vyne stock with a combined basis of $100 (or $0.50 per share). After the 1 for 50 stock split – the shareholder would hold 4 shares of Vyne stock with a combined basis of $100 (or $25 / share).